Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus

Journal of Clinical Microbiology

Volumn 48, Issue 10, 2010, Pages 3517-3524

  Operario, Darwin J ^a   Moser, Michael J ^b,c   St George, Kirsten ^a  

^a WADSWORTH CENTER   (United States)

^b EraGen Biosciences   (United States)

^c LUCIGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ARTICLE; GENE DOSAGE; GENOTYPE; INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; OUTCOME ASSESSMENT; PANDEMIC; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REACTION OPTIMIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; EUROPE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 77957801261     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01031-10     Document Type: Article

References (29)

1. Belshe, R. B., M. H. Smith, C. B. Hall, R. Betts, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1508-1512.
2. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
3. Bright, R. A., D. Shay, J. Bresee, A. Klimov, N. Cox, and J. Ortiz. 2006. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-2006 influenza season. MMWR Morb. Mortal. Wkly. Rep. 55:44-46.
4. CDC. 2008. 2007-08 U.S. influenza season summary. Centers for Disease Control and Prevention, Atlanta, GA.
5. CDC. 2009. 2008-2009 influenza season week 39 ending October 3, 2009. Centers for Disease Control and Prevention, Atlanta, GA.
6. CDC. 2010. 2009-2010 influenza season week 14 ending April 10, 2010. Centers for Disease Control and Prevention, Atlanta, GA.
7. Deyde, V. M., and L. V. Gubareva. 2009. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Rev. Mol. Diagn. 9:493-509.
8. Deyde, V. M., M. Okomo-Adhiambo, T. G. Sheu, T. R. Wallis, A. Fry, N. Dharan, A. I. Klimov, and L. V. Gubareva. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81:16-24.
9. Drinka, P. J., and T. Haupt. 2007. Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltamivir treatment of symptomatic cases. J. Am. Geriatr. Soc. 55:923-926.
10. Hurt, A. C., J. Ernest, Y. M. Deng, P. Iannello, T. G. Besselaar, C. Birch, P. Buchy, M. Chittanganpitch, S. C. Chiu, D. Dwyer, A. Guigon, B. Harrower, I. P. Kei, T. Kok, C. Lin, K. McPhie, A. Mohd, R. Olveda, T. Panayotou, W. Rawlinson, L. Scott, D. Smith, H. D'Souza, N. Komadina, R. Shaw, A. Kelso, and I. G. Barr. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
11. Jefferson, T., M. Jones, P. Doshi, and C. Del Mar. 2009. Neuraminidase inhibitors for preventing and treating influenza in health adults: systematic review and meta-analysis. BMJ 339:b5106.
12. Johnson, S. C., C. B. Sherrill, D. J. Marshall, M. J. Moser, and J. R. Prudent. 2004. A third base pair for the polymerase chain reaction: inserting isoC and isoG. Nucleic Acids Res. 32:1937-1941.
13. Lackenby, A., O. Hungnes, S. G. Dudman, A. Meijer, W. J. Paget, A. J. Hay, and M. C. Zambon. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13:8026.
14. Laplante, J. M., S. A. Marshall, M. Shudt, T. T. Van, E. S. Reisdorf, L. A. Mingle, P. A. Shult, and K. St. George. 2009. Influenza antiviral resistance testing in New York and Wisconsin, 2006-2008: methodology and surveillance data. J. Clin. Microbiol. 47:1372-1378.
15. Marshall, D. J., E. Reisdorf, G. Harms, E. Beaty, M. J. Moser, W. M. Lee, J. E. Gern, F. S. Nolte, P. Shult, and J. R. Prudent. 2007. Evaluation of a multiplexed PCR assay for detection of respiratory viral pathogens in a public health laboratory setting. J. Clin. Microbiol. 45:3875-3882.
16. Monto, A. S. 2009. The risk of seasonal and pandemic influenza: prospects for control. Clin. Infect. Dis. 1:S20-S25.
17. Monto, A. S., J. L. M. McKimm-Breschkin, C. Macken, A. W. Hampson, A. Hay, A. Klimov, M. Tashiro, R. G. Webster, M. Aymard, F. G. Hayden, and M. Zambon. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402.
18. Moser, M. J., D. R. Christensen, D. Norwood, and J. R. Prudent. 2006. Multiplexed detection of anthrax-related toxin genes. J. Mol. Diagn. 8:89-96.
19. Moser, M. J., M. Ruckstuhl, C. A. Larsen, A. J. Swearingen, M. Kozlowski, L. Bassit, P. L. Sharma, R. F. Schinazi, and J. R. Prudent. 2005. quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49:3334-3340.
20. Mulligan, E. K., J. J. Germer, M. Q. Arens, K. L. D'Amore, A. Di Bisceglie, N. A. Ledeboer, M. J. Moser, A. C. Newman, A. K. O'Guin, P. D. Olivo, D. S. Podzorski, K. A. Vaughan, J. D. Yao, S. A. Elagin, and S. C. Johnson. 2009. Detection and quantification of hepatitis C (HCV) by MultiCode-RTx realtime PCR targeting the HCV 3′ untranslated region. J. Clin. Microbiol. 47:2635-2638.
21. Nelson, M. I., L. Simonsen, C. Viboud, M. A. Miller, and E. C. Holmes. 2009. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388:270-278.
22. Prudent, J. R. 2006. Using expanded genetic alphabets to simplify high-throughput genetic testing. Expert Rev. Mol. Diagn. 6:245-252.
23. Sherrill, C. B., D. J. Marshall, M. J. Moser, C. A. Larsen, L. Daude-Snow, and J. R. Prudent. 2004. Nucleic acid analysis using an expanded genetic alphabet to quench fluorescence. J. Am. Chem. Soc. 126:4550-4556.
24. Sheu, T. G., V. M. Deyde, M. Okomo-Adhiambo, R. J. Garten, X. Xu, R. A. Bright, E. N. Butler, T. R. Wallis, A. I. Klimov, and L. V. Gubareva. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004-2008. Antimicrob. Agents Chemother. 52:3284-3292.
25. Shun-Shin, M., M. Thompson, C. Heneghan, R. Perera, A. Harnden, and D. Mant. 2009. Neuraminidase inhibitors for treatment and prophylaxis in children: systematic review and meta-analysis of randomised controlled trials. BMJ 339:b3172.
26. Svarovskaia, E. S., J. Y. Feng, N. A. Margot, F. Myrick, D. Goodman, J. K. Ly, K. L. White, N. Kutty, R. Wang, K. Borroto-Esoda, and M. D. Miller. 2008. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48:428-436.
27. Svarovskaia, E. S., M. J. Moser, A. S. Bae, J. R. Prudent, M. D. Miller, and K. Borroto-Esoda. 2006. MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J. Clin. Microbiol. 44:4237-4241.
28. Ward, P., I. Small, J. Smith, P. Suter, and R. Dutkowski. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55:i5-i21.
29. WHO. 2010. Weekly update on oseltamivir resistance to pandemic influenza A (H1N1) 2009 viruses - April 14, 2010. World Health Organization, Geneva, Switzerland.